Topics

IPF is a remorseless disease, but drugmakers are stepping up efforts towards one target: a 'master regulator' of fibrosis. Read about it in Nature Biotechnology's February issue. https://doi.org/10.1038/s41587-020-0415-5 …pic.twitter.com/dq4E4KIXIM

12:34 EST 14 Feb 2020 | Nature Publishing

IPF is a remorseless disease, but drugmakers are stepping up efforts towards one target: a 'master regulator' of fibrosis. Read about it in Nature Biotechnology's February issue. https://doi.org/10.1038/s41587-020-0415-5 …

Original Article: IPF is a remorseless disease, but drugmakers are stepping up efforts towards one target: a 'master regulator' of fibrosis. Read about it in Nature Biotechnology's February issue. https://doi.org/10.1038/s41587-020-0415-5 …pic.twitter.com/dq4E4KIXIM

NEXT ARTICLE

More From BioPortfolio on "IPF is a remorseless disease, but drugmakers are stepping up efforts towards one target: a 'master regulator' of fibrosis. Read about it in Nature Biotechnology's February issue. https://doi.org/10.1038/s41587-020-0415-5 …pic.twitter.com/dq4E4KIXIM"

Quick Search

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...